Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,448,600 | -2,494,000 | 1,099,600 | 3,619,600 | 2,650,800 |
| Depreciation Amortization | 160,700 | 107,500 | 53,500 | 181,300 | 122,300 |
| Income taxes - deferred | -400,400 | -277,100 | -158,300 | -536,500 | -405,500 |
| Accounts receivable | -168,300 | -116,500 | -251,600 | -84,100 | -99,500 |
| Accounts payable and accrued liabilities | 41,100 | -25,000 | 100 | 48,700 | 80,500 |
| Other Working Capital | 45,400 | -112,100 | 129,300 | -265,700 | 573,200 |
| Other Operating Activity | 692,900 | 470,200 | 434,000 | 574,000 | 380,900 |
| Operating Cash Flow | $-1,077,200 | $-2,447,000 | $1,306,600 | $3,537,300 | $3,302,700 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -205,100 | -137,400 | -68,400 | -200,400 | -142,300 |
| Net Acquisitions | N/A | -258,000 | N/A | N/A | N/A |
| Purchase Of Investment | -5,279,600 | -3,895,100 | -2,598,500 | -3,786,500 | -2,798,000 |
| Sale Of Investment | 3,005,400 | 1,893,100 | 710,500 | 934,200 | 716,100 |
| Purchase Sale Intangibles | -187,700 | -187,700 | -180,000 | -58,000 | 0 |
| Other Investing Activity | -468,800 | -202,700 | -180,000 | -89,000 | -31,000 |
| Investing Cash Flow | $-2,948,100 | $-2,600,100 | $-2,136,400 | $-3,141,700 | $-2,255,200 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -32,300 | -26,900 | -13,200 | -44,900 | -32,900 |
| Common Stock Issued | 80,300 | 71,900 | 16,900 | 134,600 | 88,200 |
| Common Stock Repurchased | -759,200 | -451,500 | -131,200 | -427,600 | -278,100 |
| Other Financing Activity | -392,400 | -309,600 | -230,000 | -224,300 | -219,600 |
| Financing Cash Flow | $-1,103,600 | $-716,100 | $-357,500 | $-562,200 | $-442,400 |
| Exchange Rate Effect | 4,700 | -18,100 | -15,600 | 26,900 | -500 |
| Beginning Cash Position | 10,372,300 | 10,372,300 | 10,372,300 | 10,512,000 | 10,512,000 |
| End Cash Position | 5,248,100 | 4,591,000 | 9,169,400 | 10,372,300 | 11,116,600 |
| Net Cash Flow | $-5,124,200 | $-5,781,300 | $-1,202,900 | $-139,700 | $604,600 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,077,200 | -2,447,000 | 1,306,600 | 3,537,300 | 3,302,700 |
| Capital Expenditure | -205,100 | -137,400 | -68,400 | -200,400 | -142,300 |
| Free Cash Flow | -1,282,300 | -2,584,400 | 1,238,200 | 3,336,900 | 3,160,400 |